DK1299727T3 - Hidtil ukendt tumorantigen, der er egnet til diagnosticering og behandling af blære-, ovarie-, lunge-, og nyrecancertyper - Google Patents
Hidtil ukendt tumorantigen, der er egnet til diagnosticering og behandling af blære-, ovarie-, lunge-, og nyrecancertyperInfo
- Publication number
- DK1299727T3 DK1299727T3 DK01984181T DK01984181T DK1299727T3 DK 1299727 T3 DK1299727 T3 DK 1299727T3 DK 01984181 T DK01984181 T DK 01984181T DK 01984181 T DK01984181 T DK 01984181T DK 1299727 T3 DK1299727 T3 DK 1299727T3
- Authority
- DK
- Denmark
- Prior art keywords
- prss2
- lung
- compositions
- bladder
- diagnosis
- Prior art date
Links
- 206010005003 Bladder cancer Diseases 0.000 title abstract 3
- 208000008839 Kidney Neoplasms Diseases 0.000 title abstract 3
- 206010058467 Lung neoplasm malignant Diseases 0.000 title abstract 3
- 206010033128 Ovarian cancer Diseases 0.000 title abstract 3
- 206010061535 Ovarian neoplasm Diseases 0.000 title abstract 3
- 206010038389 Renal cancer Diseases 0.000 title abstract 3
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 title abstract 3
- 201000010982 kidney cancer Diseases 0.000 title abstract 3
- 210000004072 lung Anatomy 0.000 title abstract 3
- 201000005202 lung cancer Diseases 0.000 title abstract 3
- 208000020816 lung neoplasm Diseases 0.000 title abstract 3
- 201000005112 urinary bladder cancer Diseases 0.000 title abstract 3
- 238000003745 diagnosis Methods 0.000 title abstract 2
- 206010028980 Neoplasm Diseases 0.000 title 1
- 239000000427 antigen Substances 0.000 title 1
- 102000036639 antigens Human genes 0.000 title 1
- 108091007433 antigens Proteins 0.000 title 1
- 230000002611 ovarian Effects 0.000 title 1
- 239000000203 mixture Substances 0.000 abstract 5
- 230000010261 cell growth Effects 0.000 abstract 2
- 210000001672 ovary Anatomy 0.000 abstract 2
- 108090000623 proteins and genes Proteins 0.000 abstract 2
- 230000001225 therapeutic effect Effects 0.000 abstract 2
- 238000002560 therapeutic procedure Methods 0.000 abstract 2
- 210000003932 urinary bladder Anatomy 0.000 abstract 2
- 108091026890 Coding region Proteins 0.000 abstract 1
- 102000012479 Serine Proteases Human genes 0.000 abstract 1
- 108010022999 Serine Proteases Proteins 0.000 abstract 1
- 230000004075 alteration Effects 0.000 abstract 1
- 239000003098 androgen Substances 0.000 abstract 1
- 238000009175 antibody therapy Methods 0.000 abstract 1
- 239000012472 biological sample Substances 0.000 abstract 1
- 229940022399 cancer vaccine Drugs 0.000 abstract 1
- 238000009566 cancer vaccine Methods 0.000 abstract 1
- 210000000170 cell membrane Anatomy 0.000 abstract 1
- 239000002299 complementary DNA Substances 0.000 abstract 1
- 238000002405 diagnostic procedure Methods 0.000 abstract 1
- 239000012634 fragment Substances 0.000 abstract 1
- 239000003550 marker Substances 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 229920001184 polypeptide Polymers 0.000 abstract 1
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 1
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 1
- 210000002307 prostate Anatomy 0.000 abstract 1
- 102000004169 proteins and genes Human genes 0.000 abstract 1
- 230000001105 regulatory effect Effects 0.000 abstract 1
- 239000000523 sample Substances 0.000 abstract 1
- 150000003384 small molecules Chemical class 0.000 abstract 1
- 239000003053 toxin Substances 0.000 abstract 1
- 231100000765 toxin Toxicity 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
- C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
- C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
- C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
- C12N9/6424—Serine endopeptidases (3.4.21)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/136—Screening for pharmacological compounds
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Immunology (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Urology & Nephrology (AREA)
- Wood Science & Technology (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Pathology (AREA)
- Biochemistry (AREA)
- Reproductive Health (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Rheumatology (AREA)
- Analytical Chemistry (AREA)
- Biotechnology (AREA)
- Ophthalmology & Optometry (AREA)
- Microbiology (AREA)
- Physical Education & Sports Medicine (AREA)
- Endocrinology (AREA)
- Physics & Mathematics (AREA)
- General Engineering & Computer Science (AREA)
- Dermatology (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US09/615,285 US7037667B1 (en) | 1998-06-01 | 2000-07-12 | Tumor antigen useful in diagnosis and therapy of prostate and colon cancer |
PCT/US2001/022168 WO2002004953A2 (fr) | 2000-07-12 | 2001-07-12 | Nouvel antigene tumoral utile dans le diagnostic et le traitement de cancers de la vessie, de l'ovaire, du poumon et du rein |
Publications (1)
Publication Number | Publication Date |
---|---|
DK1299727T3 true DK1299727T3 (da) | 2009-06-15 |
Family
ID=24464750
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DK01984181T DK1299727T3 (da) | 2000-07-12 | 2001-07-12 | Hidtil ukendt tumorantigen, der er egnet til diagnosticering og behandling af blære-, ovarie-, lunge-, og nyrecancertyper |
Country Status (11)
Country | Link |
---|---|
EP (2) | EP1299727B1 (fr) |
JP (2) | JP2004511219A (fr) |
AT (1) | ATE429643T1 (fr) |
AU (1) | AU2002218786A1 (fr) |
CA (1) | CA2415923C (fr) |
CY (1) | CY1109254T1 (fr) |
DE (1) | DE60138465D1 (fr) |
DK (1) | DK1299727T3 (fr) |
ES (1) | ES2323407T3 (fr) |
PT (1) | PT1299727E (fr) |
WO (1) | WO2002004953A2 (fr) |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7037667B1 (en) | 1998-06-01 | 2006-05-02 | Agensys, Inc. | Tumor antigen useful in diagnosis and therapy of prostate and colon cancer |
WO2004097358A2 (fr) * | 2003-05-02 | 2004-11-11 | Bayer Healthcare Ag | Agents diagnostiques et therapeutiques destines a des maladies associees a la serine protease 2 transmembranaire humaine (tmprss2) |
WO2004097034A2 (fr) * | 2003-05-02 | 2004-11-11 | Bayer Healthcare Ag | Agents diagnostiques et therapeutiques destines a des maladies associees a la serine protease 4 transmembranaire humaine (tmprss4) |
ES2864529T3 (es) * | 2018-01-26 | 2021-10-14 | Regeneron Pharma | Anticuerpos y fragmentos de unión a antígeno anti-TMPRSS2 |
AU2021219671A1 (en) | 2020-02-10 | 2022-07-14 | Regeneron Pharmaceuticals, Inc. | Anti-Tmprss2 Antibodies and Antigen-Binding Fragments |
Family Cites Families (49)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4179337A (en) | 1973-07-20 | 1979-12-18 | Davis Frank F | Non-immunogenic polypeptides |
US4722848A (en) | 1982-12-08 | 1988-02-02 | Health Research, Incorporated | Method for immunizing animals with synthetically modified vaccinia virus |
US4870009A (en) | 1982-11-22 | 1989-09-26 | The Salk Institute For Biological Studies | Method of obtaining gene product through the generation of transgenic animals |
US4736866A (en) | 1984-06-22 | 1988-04-12 | President And Fellows Of Harvard College | Transgenic non-human mammals |
US5225538A (en) | 1989-02-23 | 1993-07-06 | Genentech, Inc. | Lymphocyte homing receptor/immunoglobulin fusion proteins |
US5703055A (en) | 1989-03-21 | 1997-12-30 | Wisconsin Alumni Research Foundation | Generation of antibodies through lipid mediated DNA delivery |
US5723286A (en) | 1990-06-20 | 1998-03-03 | Affymax Technologies N.V. | Peptide library and screening systems |
ES2264239T3 (es) | 1990-06-27 | 2006-12-16 | Princeton University | Complejo de proteinas p53/p90'. |
SE9002480D0 (sv) | 1990-07-23 | 1990-07-23 | Hans Lilja | Assay of free and complexed prostate-specific antigen |
WO1993000109A1 (fr) | 1991-06-28 | 1993-01-07 | Genentech, Inc. | Procede de stimulation de la reponse immunitaire a l'aide d'hormone de croissance |
US5733731A (en) | 1991-10-16 | 1998-03-31 | Affymax Technologies N.V. | Peptide library and screening method |
US5674682A (en) | 1992-10-29 | 1997-10-07 | Thomas Jefferson University | Nucleic acid primers for detecting micrometastasis of prostate cancer |
US5837501A (en) | 1993-07-09 | 1998-11-17 | Akzo Nobel N.V. | Nucleic acid quantitation by co-amplification of target with multiple internal controls |
US5804566A (en) | 1993-08-26 | 1998-09-08 | The Regents Of The University Of California | Methods and devices for immunizing a host through administration of naked polynucleotides with encode allergenic peptides |
US5679647A (en) | 1993-08-26 | 1997-10-21 | The Regents Of The University Of California | Methods and devices for immunizing a host against tumor-associated antigens through administration of naked polynucleotides which encode tumor-associated antigenic peptides |
CH686982A5 (fr) | 1993-12-16 | 1996-08-15 | Maurice Stroun | Méthode pour le diagnostic de cancers. |
US5599677A (en) | 1993-12-29 | 1997-02-04 | Abbott Laboratories | Immunoassays for prostate specific antigen |
US5739118A (en) | 1994-04-01 | 1998-04-14 | Apollon, Inc. | Compositions and methods for delivery of genetic material |
US5837682A (en) | 1996-03-08 | 1998-11-17 | The Children's Medical Center Corporation | Angiostatin fragments and method of use |
EP1405911A1 (fr) | 1994-07-20 | 2004-04-07 | The General Hospital Corporation | Systèmes de détection d'intéraction permettant de décéler des intéractions entre protéines |
GB9506466D0 (en) | 1994-08-26 | 1995-05-17 | Prolifix Ltd | Cell cycle regulated repressor and dna element |
US5919652A (en) | 1994-11-09 | 1999-07-06 | The Regents Of The University Of California | Nucleic acid molecules comprising the prostate specific antigen (PSA) promoter and uses thereof |
US5736524A (en) | 1994-11-14 | 1998-04-07 | Merck & Co.,. Inc. | Polynucleotide tuberculosis vaccine |
US6071890A (en) | 1994-12-09 | 2000-06-06 | Genzyme Corporation | Organ-specific targeting of cationic amphiphile/DNA complexes for gene therapy |
US5614372A (en) | 1995-02-24 | 1997-03-25 | Lilja; Hans | Early detection of prostate cancer (CAP) by employing prostate specific antigen (PSA) and human glandular kallikrein (hGK-1) |
US5792453A (en) | 1995-02-28 | 1998-08-11 | The Regents Of The University Of California | Gene transfer-mediated angiogenesis therapy |
US5962428A (en) | 1995-03-30 | 1999-10-05 | Apollon, Inc. | Compositions and methods for delivery of genetic material |
NZ306767A (en) | 1995-04-11 | 2000-03-27 | Univ Johns Hopkins | Method of identifying molecular interactions employing counterselection and at least two hybrid molecules or two hybrid systems |
US5922687A (en) | 1995-05-04 | 1999-07-13 | Board Of Trustees Of The Leland Stanford Junior University | Intracellular delivery of nucleic acids using pressure |
CU22559A1 (es) | 1996-01-17 | 1999-05-03 | Ct Ingenieria Genetica Biotech | Sistema de expresión de antígenos heterologos en e. coli como proteínas de fusión |
US5837680A (en) | 1996-02-16 | 1998-11-17 | Children's Medical Center Corporation | Pharmaceutical compositions comprising troponin subunits, fragments and analogs thereof and methods of their use to inhibit angiogenesis |
WO1997033602A1 (fr) | 1996-03-11 | 1997-09-18 | Cytel Corporation | Peptides presentant une affinite accrue de liaison avec des molecules |
US6060449A (en) | 1996-03-25 | 2000-05-09 | Juridical Foundation The Chemo-Sero-Therapeutic Research Institute | Neovascularization inhibitor containing tissue factor pathway inhibitor |
ES2183166T3 (es) | 1996-04-26 | 2003-03-16 | Massachusetts Inst Technology | Ensayo de cribado por triple hibrido. |
DE69733756T2 (de) | 1996-05-03 | 2006-06-01 | Abbott Laboratories, Abbott Park | Antiangiogenische peptiden, dafür kodierende polynukleotide und verfahren zur hemmung der angiogenesis |
US5801146A (en) | 1996-05-03 | 1998-09-01 | Abbott Laboratories | Compound and method for inhibiting angiogenesis |
CA2262006A1 (fr) | 1996-07-26 | 1998-02-05 | Sloan-Kettering Institute For Cancer Research | Procedes et reactifs destines a l'immunisation genetique |
US5925523A (en) | 1996-08-23 | 1999-07-20 | President & Fellows Of Harvard College | Intraction trap assay, reagents and uses thereof |
ES2290964T3 (es) | 1996-10-15 | 2008-02-16 | The Regents Of The University Of California | Modelos animales de la evolucion del cancer de prostata humano. |
US5846722A (en) | 1996-10-16 | 1998-12-08 | Terrapin Technologies, Inc. | System to detect small molecule/peptide interaction |
US5840501A (en) | 1996-10-25 | 1998-11-24 | Bayer Corporation | Determination of cPSA |
AU5702298A (en) | 1996-12-03 | 1998-06-29 | Abgenix, Inc. | Transgenic mammals having human Ig loci including plural VH and VK regions nd antibodies produced therefrom |
US6043033A (en) * | 1997-02-27 | 2000-03-28 | Incyte Pharmaceuticals, Inc. | Human prostate-associated protease |
US5972615A (en) | 1998-01-21 | 1999-10-26 | Urocor, Inc. | Biomarkers and targets for diagnosis, prognosis and management of prostate disease |
PT1082341E (pt) * | 1998-06-01 | 2011-02-15 | Agensys Inc | Antigénio de tumor útil em diagnóstico e terapêutica de cancro da próstata e do cólon |
US6166194A (en) | 1998-06-29 | 2000-12-26 | Myriad Genetics, Inc. | TMPRSS2 is a tumor suppressor |
ATE413466T1 (de) * | 1998-09-02 | 2008-11-15 | Diadexus Inc | Verfahren zur diagnose, bewertung sowie bilddarstellung verschiedener krebserkrankungen |
AU6502199A (en) * | 1998-09-30 | 2000-04-17 | Millennium Pharmaceuticals, Inc. | Expression analysis of specific nucleic acids and polypeptides useful in the diagnosis and treatment of prostate cancer |
EP1131095A4 (fr) * | 1998-10-19 | 2003-04-23 | Diadexus Inc | Methode permettant de diagnostiquer, de surveiller, de classer par stades, de visualiser et de traiter le cancer de la prostate |
-
2001
- 2001-07-12 DK DK01984181T patent/DK1299727T3/da active
- 2001-07-12 JP JP2002509772A patent/JP2004511219A/ja not_active Withdrawn
- 2001-07-12 PT PT01984181T patent/PT1299727E/pt unknown
- 2001-07-12 AU AU2002218786A patent/AU2002218786A1/en not_active Abandoned
- 2001-07-12 WO PCT/US2001/022168 patent/WO2002004953A2/fr active Application Filing
- 2001-07-12 EP EP01984181A patent/EP1299727B1/fr not_active Expired - Lifetime
- 2001-07-12 CA CA2415923A patent/CA2415923C/fr not_active Expired - Fee Related
- 2001-07-12 EP EP09002403A patent/EP2075582A3/fr not_active Withdrawn
- 2001-07-12 ES ES01984181T patent/ES2323407T3/es not_active Expired - Lifetime
- 2001-07-12 DE DE60138465T patent/DE60138465D1/de not_active Expired - Lifetime
- 2001-07-12 AT AT01984181T patent/ATE429643T1/de active
-
2008
- 2008-12-25 JP JP2008329870A patent/JP2009148264A/ja active Pending
-
2009
- 2009-07-14 CY CY20091100753T patent/CY1109254T1/el unknown
Also Published As
Publication number | Publication date |
---|---|
EP1299727B1 (fr) | 2009-04-22 |
DE60138465D1 (de) | 2009-06-04 |
WO2002004953A2 (fr) | 2002-01-17 |
CA2415923C (fr) | 2011-10-25 |
WO2002004953A3 (fr) | 2002-09-19 |
EP2075582A2 (fr) | 2009-07-01 |
EP1299727A2 (fr) | 2003-04-09 |
EP2075582A3 (fr) | 2010-01-06 |
ES2323407T3 (es) | 2009-07-15 |
JP2004511219A (ja) | 2004-04-15 |
PT1299727E (pt) | 2009-07-09 |
CA2415923A1 (fr) | 2002-01-17 |
WO2002004953A8 (fr) | 2002-07-04 |
JP2009148264A (ja) | 2009-07-09 |
ATE429643T1 (de) | 2009-05-15 |
AU2002218786A1 (en) | 2002-01-21 |
CY1109254T1 (el) | 2014-07-02 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CY1111906T1 (el) | Αντιγονο ογκων χρησιμο για τη διαγνωση και θεραπεια καρκινου του προστατη και του παχεος εντερου | |
DK0444181T3 (da) | C-erbB-2 eksternt domæne: gp75 | |
CA2286304A1 (fr) | Pca3, genes de pca3, et procedes d'utilisation | |
ATE549347T1 (de) | Gene von säugetiere, und damit verbundene reagentien, methoden | |
ATE426167T1 (de) | Auto-antikírper gegen annexin-proteine als marker fur lungenkrebs | |
ATE516304T1 (de) | Nrg-2 nukleinsäuren, polypeptide und diagnostische / therapeutische methoden | |
BR9809443A (pt) | Polipeptìdeo compreendendo uma porção antigênica de um antìgeno de m. tuberculosis, molécula de dna, vetor recombinante de expressão, célula hospedeira, processo para detecção de infecção de m. tuberculosis em uma amostra biológica, kit de diganóstico, anticorpo monoclonal, anticorpo policlonal, e, proteìna de fusão. | |
NO308310B1 (no) | Hovedsakelig rent KGF protein og dets anvendelse | |
DE602005026931D1 (de) | Verwendung von vorstufen von enkephalinen und/oder deren fragmenten in der medizinischen diagnostik | |
DE69117949D1 (de) | Mit akuter pankreatitis assoziiertes protein, mittel zur diagnose von akuter pankreatitis | |
SE9602496D0 (sv) | Method and means for producing a fibrinogen binding protein and its use in biotechnology | |
CY1109254T1 (el) | Νεο αντιγονο ογκου χρησιμο στη διαγνωση και θεραπεια καρκινων της ουροδοχου κυστης, των ωοθηκων, του πνευμονα και του νεφρου | |
ES2079621T3 (es) | Procedimiento de identificacion o de titulacion de proteinas y aplicaciones. | |
WO2005019831B1 (fr) | Procedes pour la reduction de la complexite d'un echantillon au moyen d'anticorps a des sites antigeniques de petite dimension | |
DE60034966D1 (de) | Auswertung von biologischen mitteln in lebenden zielzellen | |
EA200000845A1 (ru) | Ген, кодирующий новый маркер рака | |
DE60026733D1 (de) | Histone-deacetylase-8 proteine, nukleinsäuren und methoden zur verwendung | |
ATE418604T1 (de) | Gegen das prothrombin-fragment f1+2 gerichtete antikörper, ihre herstellung und verwendung | |
Fukamachi et al. | An animal model of preclinical diagnosis of pancreatic ductal adenocarcinomas | |
Zimmerman et al. | Identification of Protein Fragments as Pattern Features in MALDI− MS Analyses of Serum | |
FR2795414B1 (fr) | Polypeptide icbp90 et ses fragments et polynucleotides codant lesdits polypeptides et applications au diagnostic et au traitement du cancer | |
ATE521623T1 (de) | Neues, bei prostatakrebs exprimiertes gen und verwendungsverfahren | |
TH62170A (th) | วัคซีนเชื้อก่อโรค Lawsonia intracellularis | |
AR013326A1 (es) | POLIPEPTIDO AISLADO, MOLECULA DE ADN, VECTOR DE EXPRESION RECOMBINANTE, CELULA HUESPED, METODO PARa DETECTAR LA INFECCION DE M.TUBERCULOSIS EN UNAMUESTRA BIOLOGICA, EQUIPO PARA DIAGNOSTICO, ANTICUERPO MONOCLONAL, Y ANTICUERPO POLICLONAL, PROTEINAS DE FUSION | |
EP1482038A4 (fr) | Nouvelle proteine et adn de celle-ci |